Table 1.
Clinical trials based on experimental or targeted therapies in malignant pheochromocytoma/paraganglioma.
| Protocol IDs | Trial aim | Type | Status | Phase |
|---|---|---|---|---|
| MAW002 NCT00978211 | Investigate the role of [90Y-DOTA]-TOC and [177LuDOTA]-TOC therapy in advanced neuroendocrine cancer | Treatment | Active | II |
| SNIPP NCT00843037 | Investigate the role of sunitinib malate in patients with advanced malignant paraganglioma or pheochromocytoma cancer | Treatment | Active | II |
| NCI-2011-02588 CDR0000699430, MAYO-MC107B, MC107B, 8783, N01CM00039, N01CM00071, P30CA015083, N01CM00099, NCT01340794 | Investigate the mechanism of action of pazopanib hydrochloride in patients with advanced or progressive malignant pheochromocytoma or paraganglioma | Biomarker/laboratory analysis, treatment | Active | II |
| IGR2010/1715 2010-024621-20, MSI/A110356-31, NCT01371201 | Determine of the efficacy of sunitinib on progression-free survival at 12 months in subjects with progressive malignant pheochromocytoma and paraganglioma treated with sunitinib at a starting dose of 37.5 mg daily | Biomarker/laboratory analysis, treatment | A ctive | II |
| I206 NCT01396408 | Identify the effects of sunitinib or temsirolimus on this type of cancer; the study will begin by finding out if sunitinib can shrink the tumor; if sunitinib does not work, temsirolimus will be tested next | Treatment | Active | II |
| UPCC 23811 NCT01635907 | Evaluate the potential ability of dovitinib to shrink the tumor or slow down cancer growth in patients with certain types of neuroendocrine tumors; this study will also evaluate safety in greater detail | Treatment | Active | II |
| 140001 14-C-0001, NCT01967576 |
Evaluate the activity of axitinib (AG-013736) | Biomarker/laboratory analysis, treatment | Active | II |
| UCL/12/0499 NCT01941849 |
This phase I trial aims to determine the recommended phase II dose (RP2D) of vandetanib in combination with standard radiation therapy, 131I-mIBG, in patients with advanced pheochromocytoma and paraganglioma by assessing the safety and tolerability of the combination treatment | Treatment | Approved-not yet active | I |
NCT ID, National Clinical Trials identifier. Information based on clinical trials listed on clinicaltrials.gov (search terms: pheochromocytoma and/or paraganglioma).